Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TENX Stock Summary
In the News

Why Is Tenax Therapeutics (TENX) Stock Up 149% Today?
Tenax Therapeutics (NASDAQ: TENX ) stock is rocketing higher on Thursday after getting an update on one of its patents. That includes a Notice of Allowance from the USPTO.

Why Is Tenax Therapeutics (TENX) Stock On the Move Today?
Tenax Therapeutics (NASDAQ: TENX ) stock is on the move Wednesday after the company announced plans for a reverse stock split. At 5:00 p.m.

7 Cheap Penny Stocks To Buy For Under $1 Right Now
Penny stocks under $1: Are they worth the risk to buy right now? The post 7 Cheap Penny Stocks To Buy For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX
New York, New York--(Newsfile Corp. - July 16, 2021) - Levi & Korsinsky announces it has commenced an investigation of Tenax Therapeutics, Inc (NASDAQ: TENX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/tenax-therapeutics-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

TENX Stock Price Increases Over 12% Pre-Market: Why It Happened
The stock price of Tenax Therapeutics Inc (NASDAQ: TENX) increased by over 12% pre-market. This is why it happened.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX
New York, New York--(Newsfile Corp. - June 7, 2021) - Levi & Korsinsky announces it has commenced an investigation of Tenax Therapeutics, Inc (NASDAQ: TENX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/tenax-therapeutics-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces first quarter 2021 financial results and provides business update.

Tenax Therapeutics Stock Price Increased Over 35% Intraday: Why It Happened
The stock price of Tenax Therapeutics (NASDAQ: TENX) increased by over 35% during intraday trading. This is why it happened.

Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax announced that Ronald R. Blanck, D.O., Gregory Pepin and Chris A. Rallis have voluntarily agreed to step down from the Board of Directors.

Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) today reported financial results for the year ended December 31, 2020 and provided a business update
TENX Financial details
TENX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -6.27 | -4.35 | -1.35 | 1.33 | -1.58 | |
Operating cash flow per share | -8.61 | -3.51 | -1.22 | -1.25 | -0.53 | |
Free cash flow per share | -8.61 | -3.52 | -1.22 | -1.25 | -0.53 | |
Cash per share | 5.48 | 8.22 | 0.87 | 0.91 | 0.27 | |
Book value per share | 6.3 | 7.52 | 0.61 | 0.62 | 0.21 | |
Tangible book value per share | 6.3 | 7.52 | 0.61 | 0.96 | 0.21 | |
Share holders equity per share | 6.3 | 7.52 | 0.61 | 0.62 | 0.21 | |
Interest debt per share | 0 | 0 | 0.02 | 0.02 | 0.01 | |
Market cap | 9.03M | 1.83M | 8.43M | 17.06M | 13.19M | |
Enterprise value | 7.42M | -10.54M | 3.63M | 10.99M | 7.9M | |
P/E ratio | -1.02 | -0.27 | -1 | 1.73 | -0.41 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -0.74 | -0.33 | -1.12 | -1.84 | -1.21 | |
PFCF ratio | -0.74 | -0.33 | -1.11 | -1.84 | -1.21 | |
P/B Ratio | 1.02 | 0.16 | 2.23 | 3.69 | 3.11 | |
PTB ratio | 1.02 | 0.16 | 2.23 | 3.69 | 3.11 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -0.84 | 1.55 | -0.44 | 1.1 | -0.24 | |
EV to operating cash flow | -0.61 | 1.92 | -0.48 | -1.18 | -0.73 | |
EV to free cash flow | -0.61 | 1.91 | -0.48 | -1.18 | -0.73 | |
Earnings yield | -0.98 | -3.72 | -1 | 0.58 | -2.46 | |
Free cash flow yield | -1.35 | -3.01 | -0.9 | -0.54 | -0.82 | |
Debt to equity | 0 | 0 | 0 | 0 | 0.04 | |
Debt to assets | 0.1 | 0.12 | 0.41 | 0.02 | 0.29 | |
Net debt to EBITDA | 0.18 | 1.82 | 0.58 | -0.61 | 0.16 | |
Current ratio | 7.99 | 8.51 | 2.44 | 3.21 | 3.64 | |
Interest coverage | 0 | 0 | 0 | -6.07K | -34.49K | |
Income quality | 1.37 | 0.81 | 0.9 | -0.94 | 0.33 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.33 | -0.84 | -0.03 | -0.03 | -0.05 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 29.8 | 27.15 | 4.31 | 4.32 | 2.71 | |
ROIC | -1.04 | -0.59 | -2.23 | -1.92 | -7.39 | |
Return on tangible assets | -0.89 | -0.51 | -1.32 | 1.36 | -5.42 | |
Graham Net | 4.79 | 7.22 | 0.45 | 0.89 | 0.19 | |
Working capital | 7.05M | 11.75M | 3.65M | 4.68M | 4.13M | |
Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
Net current asset value | 7.05M | 11.75M | 3.59M | 6.67M | 3.94M | |
Invested capital | 0 | 0 | 0.03 | 0.04 | 0.07 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 684.86K | 753.84K | 1.21M | 757.86K | 808.75K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1 | -0.58 | -2.23 | 2.13 | -7.65 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.15 | -0.13 | -0.11 | -0.11 | -0.11 | |
Operating cash flow per share | -0.12 | -0.11 | -0.12 | -0.14 | -0.13 | |
Free cash flow per share | -0.12 | -0.11 | -0.12 | -0.14 | -0.13 | |
Cash per share | 0.33 | 0.22 | 0.11 | 0.29 | 0.14 | |
Book value per share | 0.29 | 0.17 | 0.06 | 0.27 | 0.15 | |
Tangible book value per share | 0.29 | 0.17 | 0.06 | 0.27 | 0.15 | |
Share holders equity per share | 0.29 | 0.17 | 0.06 | 0.27 | 0.15 | |
Interest debt per share | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | |
Market cap | 44.61M | 26.21M | 20.42M | 7.56M | 4.48M | |
Enterprise value | 36.57M | 20.92M | 18.04M | 663.81K | 881.31K | |
P/E ratio | -2.94 | -2.04 | -1.88 | -0.66 | -0.38 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -14.76 | -9.47 | -6.95 | -2.2 | -1.34 | |
PFCF ratio | -14.75 | -9.46 | -6.94 | -2.2 | -1.34 | |
P/B Ratio | 6.16 | 6.17 | 12.71 | 1.11 | 1.13 | |
PTB ratio | 6.16 | 6.17 | 12.71 | 1.11 | 1.13 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -9.69 | -6.57 | -6.7 | -0.23 | -0.31 | |
EV to operating cash flow | -12.1 | -7.56 | -6.14 | -0.19 | -0.26 | |
EV to free cash flow | -12.1 | -7.55 | -6.13 | -0.19 | -0.26 | |
Earnings yield | -0.09 | -0.12 | -0.13 | -0.38 | -0.65 | |
Free cash flow yield | -0.07 | -0.11 | -0.14 | -0.45 | -0.74 | |
Debt to equity | 0.03 | 0.04 | 0.1 | 0.02 | 0.02 | |
Debt to assets | 0.19 | 0.29 | 0.57 | 0.19 | 0.17 | |
Net debt to EBITDA | 2.13 | 1.66 | 0.88 | 2.44 | 1.24 | |
Current ratio | 5.87 | 3.64 | 1.75 | 5.6 | 6.54 | |
Interest coverage | 0 | 0 | 1.05K | 1.93K | 7.84K | |
Income quality | 0.8 | 0.86 | 1.08 | 1.2 | 1.14 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.06 | -0.06 | -0.23 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.99 | 0.69 | 0.39 | 0.83 | 0.61 | |
ROIC | -0.51 | -0.73 | 1.54 | 0.41 | 0.72 | |
Return on tangible assets | -0.43 | -0.54 | -0.73 | -0.34 | -0.62 | |
Graham Net | 0.27 | 0.15 | 0.03 | 0.22 | 0.11 | |
Working capital | 7.12M | 4.13M | 1.48M | 6.66M | 3.82M | |
Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
Net current asset value | 6.91M | 3.94M | 1.32M | 6.53M | 3.73M | |
Invested capital | 0.04 | 0.07 | 0.31 | 0.05 | 0.05 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 847.82K | 889.51K | 1.1M | 919.38K | 592.4K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.52 | -0.76 | -1.69 | -0.42 | -0.74 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
TENX Frequently Asked Questions
What is Tenax Therapeutics, Inc. stock symbol ?
Tenax Therapeutics, Inc. is a US stock , located in Morrisville of Nc and trading under the symbol TENX
What is Tenax Therapeutics, Inc. stock quote today ?
Tenax Therapeutics, Inc. stock price is $1.75 today.
Is Tenax Therapeutics, Inc. stock public?
Yes, Tenax Therapeutics, Inc. is a publicly traded company.